Great Novel Therapeutics Biotech & Medicals reported earnings results for the half year ended June 30, 2022. For the half year, the company reported sales was TWD 0.54 million compared to TWD 0.3 million a year ago. Net loss was TWD 28.65 million compared to TWD 17.42 million a year ago.

Basic loss per share from continuing operations was TWD 1.27 compared to TWD 0.89 a year ago. Diluted loss per share from continuing operations was TWD 1.27 compared to TWD 0.89 a year ago.